Canadian Pulmonary Radiotherapy Investigators Group
  • Home
  • Trials
  • Our Team
  • Contact

CAPRI Clinical Trials

Below is a list of clinical trials run by the CAPRI group.

To obtain a protocol or open a trial at your centre, please use the contact information below.

PROACTIVE
A randomized phase III study of Palliative Radiation of Advanced Central Tumors with Intentional avoidance of the Esophagus

Picture
Picture
Study Question: 
    Can esophageal sparing improve quality of life for patients
    receiving palliative radiation for non-small cell lung cancer?

Principal Investigators: 
    Dr. Alexander Louie (Radiation Oncology)
    Dr. Patrick Granton (Radiation Physics)

Target Accrual:  90 patients (45 patients in each arm)

Current Accrual:  90/90 patients

Current Status:  Published in JAMA Oncology



PET-BOOST
A randomized phase II trial to assess the efficacy and safety of selective metabolically adaptive radiation dose escalation in locally advanced non-small cell lung cancer receiving definitive chemoradiotherapy

Picture
Study Question:
 
   In stage III non-small cell lung cancer patients receiving
    chemoradiation, dose dose escalation to metabolically active
    tumor volumes improve locoregional control and overall
    survival?

Principal Investigators:
    Dr. Alex Sun (Radiation Oncology)
    Dr. Jean-Pierre Bissonnette (Radiation Physics)

Target Accrual:  74 patients (37 patients in each arm)

Current Accrual:  74/74 patients

Current Status:  Data Maturing, Analysis Expected in 2023

ClinicalTrials.gov Identifier:  NCT02788461



STOP
Stereotactic radiotherapy for oligo-progressive cancers:  A randomized phase II trial

Picture
Study Question:
    What is the impact of stereotactic radiation in patients with
    metastatic non-small cell lung cancer who have oligo-
    progressive disease while on systemic therapy?

Principal Investigators:
   
Dr. Devin Schellenberg (Radiation Oncology)
    Dr. Patrick Cheung (Radiation Oncology)

Target Accrual:  90 patients
                           
Current Accrual:  90/90 patients

Current Status:  Data Maturing, Analysis Expected in 2023​

ClinicalTrials.gov Identifier:  NCT02756793



SUNSET
Stereotactic body radiotherapy for ultra-central non-small cell lung cancer:  A safety and efficacy trial

Picture
Study Question:
    What is the maximally tolerated dose of radiotherapy for
    ultracentral non-small cell lung carcinoma associated with a
    30% or lower rate of grade 3-5 toxicity occurring within 2
    years of treatment?

Principal Investigator:
   
Dr. Meredith Giuliani (Radiation Oncology)

Target Accrual:  30 patients

Current Accrual:  30/30 patients

Current Status:  Data Maturing, Analysis Expected in 2022

ClinicalTrials.gov Identifier:  NCT03306680



ASPIRE-ILD
Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease:  A phase II trial

Picture
Study Question:
 What are the survival and toxicity outcomes associated with the use of SABR in patients with ILD?

Principal Investigators:
   
Dr. David Palma (Radiation Oncology)
    Dr. Alexander Louie (Radiation Oncology)
    Dr. Chris Ryerson (Respirology)

Target Accrual:  39 patients

Current Accrual:  39/39 patients
                           
Current Status:  Data Maturing, Analysis Expected in 2023​

ClinicalTrials.gov Identifier:  NCT03485378



Selection of Trials for CAPRI

Trial proposals are solicited from investigators across Canada. All trials are peer-reviewed in a double-blind process by both Canadian and International experts. Proposals are scored based on novelty, scientific relevance, feasibility, methodology, and potential for clinical impact. If you are an investigator wishing to propose a trial, please contact us below.

Funding of CAPRI Trials

CAPRI trials are funded through philanthropic donations made to the London Health Sciences Foundation, and operating research funds from the Ontario Institute for Cancer Research.

Contact CAPRI

Click here to send us a message or inquire about one of the trials.

Photo used under Creative Commons from Tony Webster
  • Home
  • Trials
  • Our Team
  • Contact